Why did reported net income decline while adjusted net income grew?

Reported Q2 net income fell 7% to $624 million, partly because Q2 2023 included a $101 million net gain on the sale of a majority interest in the pet insurance business. Adjusted net income excludes purchase accounting adjustments, acquisition and divestiture costs, and certain significant items such as restructuring and asset impairments. On that basis, adjusted net income rose 9% to $711 million, and 18% operationally.

How much of the growth came from currency versus underlying business performance?

Foreign exchange was a significant headwind. Total revenue grew 8% reported but 11% operationally, a roughly 3-point currency drag. The drag was concentrated internationally, where reported revenue grew 4% against 10% operational growth. Adjusted net income was hit harder, with a 9-point FX impact that lowered reported growth to 9% from 18% operationally.

Why did management raise guidance, and what risks remain?

Management attributed the raise to a strong first half and underlying strength in companion animal products. The guidance reflects late-July FX rates, and the company notes it cannot reasonably forecast the FX impact of unusual items, so reported results could differ materially from the operational outlook. Sustaining the second-half pace will depend on continued adoption of its newer franchises and on international currency conditions.

What is the gap between reported and adjusted full-year guidance?

Reported diluted EPS guidance is $5.35 to $5.45, versus adjusted guidance of $5.78 to $5.88. The gap is about $0.19 from certain significant items and acquisition/divestiture costs (roughly $80 to $90 million pre-tax) and about $0.24 from purchase accounting adjustments (roughly $110 million net income impact). Investors should weigh the reported figures alongside the non-GAAP measures.

ZTS 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed August 6, 2024. Cited figures are marked; the original filing is the authoritative source.

Zoetis (NYSE: ZTS) reported second quarter 2024 results on August 6, 2024, delivering revenue of $2.36 billion^a, up 8% on a reported basis and 11% on an operational (currency-neutral) basis.

Reported net income was $624 million^b, or $1.37 per diluted share, down 7% and 6% respectively, largely reflecting higher operating costs, R&D spending, and a swing from a prior-year $101 million gain on the sale of a pet insurance business. On a non-GAAP adjusted basis, net income rose 9% to $711 million, or $1.56 per diluted share (up 11%), and grew 18% operationally, a stronger picture of underlying profitability. Growth was led by the U.S. (up 12%) and companion animal products, notably osteoarthritis pain mAbs Librela and Solensia, Simparica Trio, and dermatology products Apoquel and Cytopoint.

Management raised full-year 2024 guidance, now calling for revenue of $9.100 to $9.250 billion^c (9% to 11% operational growth), adjusted net income of $2.640 to $2.690 billion (13.5% to 15.5% operational growth), and adjusted diluted EPS of $5.78 to $5.88. Reported diluted EPS guidance is $5.35 to $5.45, with the gap driven primarily by roughly $80 to $90 million of certain significant items and acquisition/divestiture costs and about $110 million of purchase accounting adjustments.

The guidance reflects foreign exchange rates as of late July 2024. Investors should note that international operational growth of 10%^d contrasted with a 6% headwind from currency, and that the company relies heavily on non-GAAP measures, which the filing reconciles to GAAP figures.

02—Key points

Key Highlights

Q2 2024 revenue of $2.36 billion rose 8% reported and 11% operationally, with U.S. revenue up 12% and International up 4% reported and 10% operationally.
Reported Q2 diluted EPS was $1.37, down 6% year over year, while adjusted diluted EPS was $1.56, up 11% reported and 20% operationally.
Companion animal revenue grew 11% reported and 12% operationally to $1.65 billion, while livestock grew 3% reported and 9% operationally to $694 million.
Full-year 2024 revenue guidance was raised to $9.100 to $9.250 billion, with operational growth of 9% to 11%.
Full-year adjusted diluted EPS guidance of $5.78 to $5.88 implies a reported EPS range of $5.35 to $5.45, with the difference driven by purchase accounting and significant items.
Q2 reported operating expenses rose, with R&D up 17% to $171 million and cost of sales up 10%, weighing on reported margins.
Key growth drivers included Librela and Solensia for osteoarthritis pain, Simparica Trio, and dermatology products Apoquel and Cytopoint.

03—Questions

Frequently Asked Questions

Why did reported net income decline while adjusted net income grew?
Reported Q2 net income fell 7% to $624 million, partly because Q2 2023 included a $101 million net gain on the sale of a majority interest in the pet insurance business. Adjusted net income excludes purchase accounting adjustments, acquisition and divestiture costs, and certain significant items such as restructuring and asset impairments. On that basis, adjusted net income rose 9% to $711 million, and 18% operationally.
How much of the growth came from currency versus underlying business performance?
Foreign exchange was a significant headwind. Total revenue grew 8% reported but 11% operationally, a roughly 3-point currency drag. The drag was concentrated internationally, where reported revenue grew 4% against 10% operational growth. Adjusted net income was hit harder, with a 9-point FX impact that lowered reported growth to 9% from 18% operationally.
Why did management raise guidance, and what risks remain?
Management attributed the raise to a strong first half and underlying strength in companion animal products. The guidance reflects late-July FX rates, and the company notes it cannot reasonably forecast the FX impact of unusual items, so reported results could differ materially from the operational outlook. Sustaining the second-half pace will depend on continued adoption of its newer franchises and on international currency conditions.
What is the gap between reported and adjusted full-year guidance?
Reported diluted EPS guidance is $5.35 to $5.45, versus adjusted guidance of $5.78 to $5.88. The gap is about $0.19 from certain significant items and acquisition/divestiture costs (roughly $80 to $90 million pre-tax) and about $0.24 from purchase accounting adjustments (roughly $110 million net income impact). Investors should weigh the reported figures alongside the non-GAAP measures.

04—Continue

← View all 8-K filings